Monopar Therapeutics Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $38.50 on 10/24/24, while the lowest price for the same duration was marked at $1.37 on 11/27/23.
52-week price history of MNPR Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Monopar Therapeutics Inc’s current trading price is -56.03% away from its 52-week high, while its distance from the 52-week low is 1136.22%. The stock’s price range during the 52-week period has remained between $1.37 and $38.50. In the Healthcare sector, the company’s shares saw a trading volume of around 3.3 million for the day, which was evidently higher than the average daily volume of 1.12 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Monopar Therapeutics Inc (MNPR) has experienced a quarterly rise of 363.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 59.59M and boasts a workforce of 10 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.20, with a change in price of +13.09. Similarly, Monopar Therapeutics Inc recorded 770,661 in trading volume during the last 100 days, posting a change of +340.37%.
Examining MNPR’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for MNPR stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
MNPR Stock Stochastic Average
As of today, Monopar Therapeutics Inc’s raw stochastic average for the last 50 days stands at 40.66%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 36.56%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 41.41% and 36.39%, respectively.
MNPR Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The metric has seen a significant gain of 895.30% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 414.43%. Over the past 30 days, the price of MNPR has fallen by 189.90%. And in the last five days, it has surged by 207.82%.
